Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus

Vitamins and Hormones

Volumn 95, Issue , 2014, Pages 195-222

  Ludwig, Barbara ^a,b,c   Barthel, Andreas ^a,f   Reichel, Andreas ^a   Block, Norman L ^d,e   Ludwig, Stefan ^a   Schally, Andrew V ^d,e   Bornstein, Stefan R ^a,b,c  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f Endokrinologikum Ruhr   (Germany)

Author keywords

Corticotrophin releasing hormone; Diabetes mellitus type 1; Diabetes mellitus type 2; Endocrine receptors; Environmental factors; Genetic factors; Glucocorticoids; Insulin; Mineralocorticoids; Nutrition; Pancreas; Pancreatic islet cells; Stress; Stress response

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ANIMAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; HUMAN; MENTAL STRESS; METABOLISM; MOLECULARLY TARGETED THERAPY; PANCREAS ISLET; PATHOPHYSIOLOGY; PHYSIOLOGICAL STRESS; SECRETION (PROCESS);

ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MOLECULAR TARGETED THERAPY; STRESS, PHYSIOLOGICAL; STRESS, PSYCHOLOGICAL;

EID: 84894027054     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800174-5.00008-9     Document Type: Chapter

References (191)

1. Achenbach P., Barker J., Bonifacio E. Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Current Diabetes Reports 2008, 8(2):87-93.
2. Achenbach P., Bonifacio E., Koczwara K., Ziegler A.G. Natural history of type 1 diabetes. Diabetes 2005, 54(Suppl. 2):S25-S31.
3. Ackermann A.M., Gannon M. Molecular regulation of pancreatic beta-cell mass development, maintenance, and expansion. Journal of Molecular Endocrinology 2007, 38(1-2):193-206.
4. Alberts P., Engblom L., Edling N., Forsgren M., Klingstrom G., Larsson C., et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002, 45(11):1528-1532.
5. Alleva D.G., Maki R.A., Putnam A.L., Robinson J.M., Kipnes M.S., Dandona P., et al. Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scandinavian Journal of Immunology 2006, 63(1):59-69.
6. Ammala C., Ashcroft F.M., Rorsman P. Calcium-independent potentiation of insulin release by cyclic AMP in single beta-cells. Nature 1993, 363(6427):356-358.
7. Aschner P., Kipnes M.S., Lunceford J.K., Sanchez M., Mickel C., Williams-Herman D.E. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29(12):2632-2637.
8. Audhya T., Jain R., Hollander C.S. Receptor-mediated immunomodulation by corticotropin-releasing factor. Cellular Immunology 1991, 134(1):77-84.
9. Bach J.F., Feutren G., Noel L.H., Hannedouche T., Landais P., Timsit J., et al. Factors predictive of cyclosporine-induced nephrotoxicity: The role of cyclosporine blood levels. Transplantation Proceedings 1990, 22(3):1296-1298.
10. Baekkeskov S., Warnock G., Christie M., Rajotte R.V., Larsen P.M., Fey S. Revelation of specificity of 64K autoantibodies in IDDM serums by high-resolution 2-D gel electrophoresis. Unambiguous identification of 64K target antigen. Diabetes 1989, 38(9):1133-1141.
11. Baisch J.M., Weeks T., Giles R., Hoover M., Stastny P., Capra J.D. Analysis of HLA-DQ genotypes and susceptibility in insulin-dependent diabetes mellitus. The New England Journal of Medicine 1990, 322(26):1836-1841.
12. Barf T., Vallgarda J., Emond R., Haggstrom C., Kurz G., Nygren A., et al. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1. Journal of Medicinal Chemistry 2002, 45(18):3813-3815.
13. Bates H.E., Sirek A.S., Kiraly M.A., Yue J.T., Goche Montes D., Matthews S.G., et al. Adaptation to mild, intermittent stress delays development of hyperglycemia in the Zucker diabetic fatty rat independent of food intake: Role of habituation of the hypothalamic-pituitary-adrenal axis. Endocrinology 2008, 149(6):2990-3001.
14. Battaglia M., Stabilini A., Draghici E., Gregori S., Mocchetti C., Bonifacio E., et al. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 2006, 55(1):40-49.
15. Battaglia M., Stabilini A., Draghici E., Migliavacca B., Gregori S., Bonifacio E., et al. Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells. Diabetes 2006, 55(6):1571-1580.
16. Battaglia M., Stabilini A., Migliavacca B., Horejs-Hoeck J., Kaupper T., Roncarolo M.G. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. The Journal of Immunology 2006, 177(12):8338-8347.
17. Bell G.I., Horita S., Karam J.H. A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes 1984, 33(2):176-183.
18. Bennett S.T., Lucassen A.M., Gough S.C., Powell E.E., Undlien D.E., Pritchard L.E., et al. Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nature Genetics 1995, 9(3):284-292.
19. Bergmann A., Li J., Wang L., Schulze J., Bornstein S.R., Schwarz P.E. A simplified Finnish diabetes risk score to predict type 2 diabetes risk and disease evolution in a German population. Hormone and Metabolic Research 2007, 39(9):677-682.
20. Bonner-Weir S., Inada A., Yatoh S., Li W.C., Aye T., Toschi E., et al. Transdifferentiation of pancreatic ductal cells to endocrine beta-cells. Biochemical Society Transactions 2008, 36(Pt 3):353-356.
21. Bonner-Weir S., Taneja M., Weir G.C., Tatarkiewicz K., Song K.H., Sharma A., et al. In vitro cultivation of human islets from expanded ductal tissue. Proceedings of the National Academy of Sciences of the United States of America 2000, 97(14):7999-8004.
22. Bornstein S.R. Is leptin a stress related peptide?. Nature Medicine 1997, 3(9):937.
23. Bornstein S.R., Abu-Asab M., Glasow A., Path G., Hauner H., Tsokos M., et al. Immunohistochemical and ultrastructural localization of leptin and leptin receptor in human white adipose tissue and differentiating human adipose cells in primary culture. Diabetes 2000, 49(4):532-538.
24. Bornstein S.R., Uhlmann K., Haidan A., Ehrhart-Bornstein M., Scherbaum W.A. Evidence for a novel peripheral action of leptin as a metabolic signal to the adrenal gland: Leptin inhibits cortisol release directly. Diabetes 1997, 46(7):1235-1238.
25. Bornstein S.R., Wong M.L., Licinio J. 150 years of Sigmund Freud: What would Freud have said about the obesity epidemic?. Molecular Psychiatry 2006, 11(12):1070-1072.
26. Bottini N., Musumeci L., Alonso A., Rahmouni S., Nika K., Rostamkhani M., et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nature Genetics 2004, 36(4):337-338.
27. Brazg R., Xu L., Dalla Man C., Cobelli C., Thomas K., Stein P.P. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes, Obesity & Metabolism 2007, 9(2):186-193.
28. Bresson D., Togher L., Rodrigo E., Chen Y., Bluestone J.A., Herold K.C., et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. The Journal of Clinical Investigation 2006, 116(5):1371-1381.
29. Buchanan T.A., Xiang A.H., Peters R.K., Kjos S.L., Marroquin A., Goico J., et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002, 51(9):2796-2803.
30. Butler A.E., Janson J., Soeller W.C., Butler P.C. Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: Evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 2003, 52(9):2304-2314.
31. Caillat-Zucman S., Garchon H.J., Timsit J., Assan R., Boitard C., Djilali-Saiah I., et al. Age-dependent HLA genetic heterogeneity of type 1 insulin-dependent diabetes mellitus. The Journal of Clinical Investigation 1992, 90(6):2242-2250.
32. Cauchi S., Meyre D., Durand E., Proenca C., Marre M., Hadjadj S., et al. Post genome-wide association studies of novel genes associated with type 2 diabetes show gene-gene interaction and high predictive value. PLoS One 2008, 3(5):e2031.
33. Chen R., Lewis K.A., Perrin M.H., Vale W.W. Expression cloning of a human corticotropin-releasing-factor receptor. Proceedings of the National Academy of Sciences of the United States of America 1993, 90(19):8967-8971.
34. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002, 359(9323):2072-2077.
35. Ciancio G., Burke G.W., Gaynor J.J., Roth D., Sageshima J., Kupin W., et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: One year follow-up. Transplantation 2008, 86(1):67-74.
36. Cibelli G., Corsi P., Diana G., Vitiello F., Thiel G. Corticotropin-releasing factor triggers neurite outgrowth of a catecholaminergic immortalized neuron via cAMP and MAP kinase signalling pathways. The European Journal of Neuroscience 2001, 13(7):1339-1348.
37. Clifton V.L., Owens P.C., Robinson P.J., Smith R. Identification and characterization of a corticotrophin-releasing hormone receptor in human placenta. European Journal of Endocrinology 1995, 133(5):591-597.
38. Combettes M., Kargar C. Newly approved and promising antidiabetic agents. Thérapie 2007, 62(4):293-310.
39. Cozar-Castellano I., Weinstock M., Haught M., Velazquez-Garcia S., Sipula D., Stewart A.F. Evaluation of beta-cell replication in mice transgenic for hepatocyte growth factor and placental lactogen: Comprehensive characterization of the G1/S regulatory proteins reveals unique involvement of p21cip. Diabetes 2006, 55(1):70-77.
40. Davani B., Khan A., Hult M., Martensson E., Okret S., Efendic S., et al. Type 1 11beta-hydroxysteroid dehydrogenase mediates glucocorticoid activation and insulin release in pancreatic islets. The Journal of Biological Chemistry 2000, 275(45):34841-34844.
41. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28(5):1092-1100.
42. Diabetes Prevention Program Research Group Strategies to identify adults at high risk for type 2 diabetes: The Diabetes Prevention Program. Diabetes Care 2005, 28(1):138-144.
43. Diabetes Prevention Trial-Type 1 Diabetes Study Group Effects of insulin in relatives of patients with type 1 diabetes mellitus. The New England Journal of Medicine 2002, 346(22):1685-1691.
44. Diederich S., Quinkler M., Burkhardt P., Grossmann C., Bahr V., Oelkers W. 11Beta-hydroxysteroid-dehydrogenase isoforms: Tissue distribution and implications for clinical medicine. European Journal of Clinical Investigation 2000, 30(Suppl. 3):21-27.
45. Ding W.G., Gromada J. Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide. Diabetes 1997, 46(4):615-621.
46. Dluhy R.G., McMahon G.T. Intensive glycemic control in the ACCORD and ADVANCE trials. The New England Journal of Medicine 2008, 358(24):2630-2633.
47. Donath M.Y., Schumann D.M., Faulenbach M., Ellingsgaard H., Perren A., Ehses J.A. Islet inflammation in type 2 diabetes: From metabolic stress to therapy. Diabetes Care 2008, 31(Suppl. 2):S161-S164.
48. Dor Y., Brown J., Martinez O.I., Melton D.A. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 2004, 429(6987):41-46.
49. Duplomb L., Lee Y., Wang M.Y., Park B.H., Takaishi K., Agarwal A.K., et al. Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone. Biochemical and Biophysical Research Communications 2004, 313(3):594-599.
50. Dupuis J., Langenberg C., Prokopenko I., Saxena R., Soranzo N., Jackson A.U., et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nature Genetics 2010, 42(2):105-116.
51. Ehrhart-Bornstein M., Lamounier-Zepter V., Schraven A., Langenbach J., Willenberg H.S., Barthel A., et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(24):14211-14216.
52. Elfaitouri A., Berg A.K., Frisk G., Yin H., Tuvemo T., Blomberg J. Recent enterovirus infection in type 1 diabetes: Evidence with a novel IgM method. Journal of Medical Virology 2007, 79(12):1861-1867.
53. Ferdaoussi M., Abdelli S., Yang J.Y., Cornu M., Niederhauser G., Favre D., et al. Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway. Diabetes 2008, 57(5):1205-1215.
54. Fischer S., Bornstein S.R. New oral antidiabetic agents-Clinical perspectives. Internist (Berlin) 2008, 49(4):495-501.
55. Foulis A.K., McGill M., Farquharson M.A. Insulitis in type 1 (insulin-dependent) diabetes mellitus in man-Macrophages, lymphocytes, and interferon-gamma containing cells. The Journal of Pathology 1991, 165(2):97-103.
56. Fronczak C.M., Baron A.E., Chase H.P., Ross C., Brady H.L., Hoffman M., et al. In utero dietary exposures and risk of islet autoimmunity in children. Diabetes Care 2003, 26(12):3237-3242.
57. Gale E.A. A missing link in the hygiene hypothesis?. Diabetologia 2002, 45(4):588-594.
58. Gale E.A., Bingley P.J., Emmett C.L., Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT): A randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004, 363(9413):925-931.
59. Garber A.J., Foley J.E., Banerji M.A., Ebeling P., Gudbjornsdottir S., Camisasca R.P., et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes, Obesity & Metabolism 2008, 10(11):1047-1056.
60. Gerstein H.C., Yusuf S., Bosch J., Pogue J., Sheridan P., Dinccag N., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 2006, 368(9541):1096-1105.
61. Gillespie K.M., Bain S.C., Barnett A.H., Bingley P.J., Christie M.R., Gill G.V., et al. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet 2004, 364(9446):1699-1700.
62. Gillies C.L., Abrams K.R., Lambert P.C., Cooper N.J., Sutton A.J., Hsu R.T., et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: Systematic review and meta-analysis. BMJ 2007, 334(7588):299.
63. Gillies C.L., Lambert P.C., Abrams K.R., Sutton A.J., Cooper N.J., Hsu R.T., et al. Different strategies for screening and prevention of type 2 diabetes in adults: Cost effectiveness analysis. BMJ 2008, 336(7654):1180-1185.
64. Golden S.H. A review of the evidence for a neuroendocrine link between stress, depression and diabetes mellitus. Current Diabetes Reviews 2007, 3(4):252-259.
65. Goldstein B.J. Clinical translation of "a diabetes outcome progression trial": ADOPT appropriate combination oral therapies in type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism 2007, 92(4):1226-1228.
66. Granata R., Settanni F., Biancone L., Trovato L., Nano R., Bertuzzi F., et al. Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic beta-cells and human islets: Involvement of 3',5'-cyclic adenosine monophosphate/protein kinase A, extracellular signal-regulated kinase 1/2, and phosphatidyl inositol 3-kinase/Akt signaling. Endocrinology 2007, 148(2):512-529.
67. Gromada J., Bokvist K., Ding W.G., Holst J.J., Nielsen J.H., Rorsman P. Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes 1998, 47(1):57-65.
68. Haffner S.M. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003, 26(Suppl. 1(1)):S83-S86.
69. Haller M.J., Viener H.L., Wasserfall C., Brusko T., Atkinson M.A., Schatz D.A. Autologous umbilical cord blood infusion for type 1 diabetes. Experimental Hematology 2008, 36(6):710-715.
70. Hanefeld M., Koehler C., Gallo S., Benke I., Ott P. Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: The Diabetes in Germany (DIG) study. Cardiovascular Diabetology 2007, 6(13):13.
71. Harding A.H., Griffin S.J., Wareham N.J. Population impact of strategies for identifying groups at high risk of type 2 diabetes. Preventive Medicine 2006, 42(5):364-368.
72. Harrison L.C., Honeyman M.C., Steele C.E., Stone N.L., Sarugeri E., Bonifacio E., et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004, 27(10):2348-2355.
73. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002, 360(9326):7-22.
74. Hermansen K., Kipnes M., Luo E., Fanurik D., Khatami H., Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes, Obesity & Metabolism 2007, 9(5):733-745.
75. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005, 54(6):1763-1769.
76. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. The New England Journal of Medicine 2002, 346(22):1692-1698.
77. Horikawa Y., Iwasaki N., Hara M., Furuta H., Hinokio Y., Cockburn B.N., et al. Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nature Genetics 1997, 17(4):384-385.
78. Horikawa Y., Oda N., Cox N.J., Li X., Orho-Melander M., Hara M., et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nature Genetics 2000, 26(2):163-175.
79. Huising M.O., van der Meulen T., Vaughan J.M., Matsumoto M., Donaldson C.J., Park H., et al. CRHR1 is expressed on pancreatic beta cells, promotes beta cell proliferation, and potentiates insulin secretion in a glucose-dependent manner. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(2):912-917.
80. Hypponen E., Laara E., Reunanen A., Jarvelin M.R., Virtanen S.M. Intake of vitamin D and risk of type 1 diabetes: A birth-cohort study. Lancet 2001, 358(9292):1500-1503.
81. Jellinger P.S., Lebovitz H.E., Davidson J.A. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes: Response to Nathan et al. Diabetes Care 2007, 30(4):e16-e17. author reply e18-20, e21-12.
82. 2+ channels in rat islet beta-cells. Pflügers Archiv 1998, 435(4):578-580.
83. Kaplan B., West P., Neeley H., Martellotto J., Iqbal R., Gangemi A., et al. Use of low dose tacrolimus, mycophenolate mofetil and maintenance IL-2 receptor blockade in an islet transplant recipient. Clinical Transplantation 2008, 22(2):250-253.
84. Kaufman D., Banerji M.A., Shorman I., Smith E.L., Coplan J.D., Rosenblum L.A., et al. Early-life stress and the development of obesity and insulin resistance in juvenile bonnet macaques. Diabetes 2007, 56(5):1382-1386.
85. Kempf K., Rathmann W., Herder C. Impaired glucose regulation and type 2 diabetes in children and adolescents. Diabetes/Metabolism Research and Reviews 2008, 24(6):427-437.
86. Kendall D.M., Riddle M.C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28(5):1083-1091.
87. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. The New England Journal of Medicine 2005, 352(25):2598-2608.
88. Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Current Medical Research and Opinion 2008, 24(1):275-286.
89. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine 2002, 346(6):393-403.
90. Knowler W.C., Hamman R.F., Edelstein S.L., Barrett-Connor E., Ehrmann D.A., Walker E.A., et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005, 54(4):1150-1156.
91. Konzem S.L., Devore V.S., Bauer D.W. Controlling hypertension in patients with diabetes. American Family Physician 2002, 66(7):1209-1214.
92. Korenblum W., Barthel A., Licinio J., Wong M.L., Wolf O.T., Kirschbaum C., et al. Elevated cortisol levels and increased rates of diabetes and mood symptoms in Soviet Union-born Jewish immigrants to Germany. Molecular Psychiatry 2005, 10(11):974-975.
93. Kostich W.A., Chen A., Sperle K., Largent B.L. Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: The CRF2gamma receptor. Molecular Endocrinology 1998, 12(8):1077-1085.
94. Kotelevtsev Y., Holmes M.C., Burchell A., Houston P.M., Schmoll D., Jamieson P., et al. 11beta-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(26):14924-14929.
95. Kupila A., Sipila J., Keskinen P., Simell T., Knip M., Pulkki K., et al. Intranasally administered insulin intended for prevention of type 1 diabetes-A safety study in healthy adults. Diabetes/Metabolism Research and Reviews 2003, 19(5):415-420.
96. Kyrou I., Tsigos C. Stress mechanisms and metabolic complications. Hormone and Metabolic Research 2007, 39(6):430-438.
97. Lamounier-Zepter V., Ehrhart-Bornstein M., Karczewski P., Haase H., Bornstein S.R., Morano I. Human adipocytes attenuate cardiomyocyte contraction: Characterization of an adipocyte-derived negative inotropic activity. FASEB Journal 2006, 20(10):1653-1659.
98. Lampeter E.F., Klinghammer A., Scherbaum W.A., Heinze E., Haastert B., Giani G., et al. The Deutsche Nicotinamide Intervention Study: An attempt to prevent type 1 diabetes. DENIS Group. Diabetes 1998, 47(6):980-984.
99. Lan M.S., Wasserfall C., Maclaren N.K., Notkins A.L. IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(13):6367-6370.
100. Lazar L., Ofan R., Weintrob N., Avron A., Tamir M., Elias D., et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: A randomised, double-blind phase II study. Diabetes/Metabolism Research and Reviews 2007, 23(4):286-291.
101. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. The New England Journal of Medicine 2001, 345(12):851-860.
102. Li H., Robinson P.J., Kawashima S., Funder J.W., Liu J.P. Differential regulation of MAP kinase activity by corticotropin-releasing hormone in normal and neoplastic corticotropes. International Journal of Biochemistry and Cell Biology 1998, 30(12):1389-1401.
103. Lindsay R.S., Lindsay R.M., Waddell B.J., Seckl J.R. Prenatal glucocorticoid exposure leads to offspring hyperglycaemia in the rat: Studies with the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone. Diabetologia 1996, 39(11):1299-1305.
104. Lindstrom J., Tuomilehto J. The diabetes risk score: A practical tool to predict type 2 diabetes risk. Diabetes Care 2003, 26(3):725-731.
105. Liu Z., Habener J.F. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. The Journal of Biological Chemistry 2008, 283(13):8723-8735.
106. Lonnrot M., Korpela K., Knip M., Ilonen J., Simell O., Korhonen S., et al. Enterovirus infection as a risk factor for beta-cell autoimmunity in a prospectively observed birth cohort: The Finnish Diabetes Prediction and Prevention Study. Diabetes 2000, 49(8):1314-1318.
107. Lovenberg T.W., Liaw C.W., Grigoriadis D.E., Clevenger W., Chalmers D.T., De Souza E.B., et al. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proceedings of the National Academy of Sciences of the United States of America 1995, 92(3):836-840.
108. Ludvigsson J. Immune intervention at diagnosis-Should we treat children to preserve beta-cell function?. Pediatric Diabetes 2007, 8(Suppl. 6):34-39.
109. Ludwig B., Rotem A., Schmid J., Weir G.C., Colton C.K., Brendel M.D., et al. Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proceedings of the National Academy of Sciences of the United States of America 2012, 109(13):5022-5027.
110. Ludwig B., Ziegler C.G., Schally A.V., Richter C., Steffen A., Jabs N., et al. Agonist of growth hormone-releasing hormone as a potential effector for survival and proliferation of pancreatic islets. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(28):12623-12628.
111. Massi-Benedetti M. Changing targets in the treatment of type 2 diabetes. Current Medical Research and Opinion 2006, 22(Suppl. 2):S5-S13.
112. Mayor S. International Diabetes Federation consensus on prevention of type 2 diabetes. International Journal of Clinical Practice 2007, 61(10):1773-1775.
113. Meier J.J. Beta cell mass in diabetes: A realistic therapeutic target?. Diabetologia 2008, 51(5):703-713.
114. Mlinar B., Marc J., Janez A., Pfeifer M. Molecular mechanisms of insulin resistance and associated diseases. Clinica Chimica Acta 2007, 375(1-2):20-35.
115. Monti P., Scirpoli M., Maffi P., Piemonti L., Secchi A., Bonifacio E., et al. Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells. Diabetes 2008, 57(9):2341-2347.
116. Mu J., Woods J., Zhou Y.P., Roy R.S., Li Z., Zycband E., et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006, 55(6):1695-1704.
117. Mziaut H., Kersting S., Knoch K.P., Fan W.H., Trajkovski M., Erdmann K., et al. ICA512 signaling enhances pancreatic beta-cell proliferation by regulating cyclins D through STATs. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(2):674-679.
118. Mziaut H., Trajkovski M., Kersting S., Ehninger A., Altkruger A., Lemaitre R.P., et al. Synergy of glucose and growth hormone signalling in islet cells through ICA512 and STAT5. Nature Cell Biology 2006, 8(5):435-445.
119. Nakayama M., Abiru N., Moriyama H., Babaya N., Liu E., Miao D., et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005, 435(7039):220-223.
120. Nejentsev S., Sjoroos M., Soukka T., Knip M., Simell O., Lovgren T., et al. Population-based genetic screening for the estimation of Type 1 diabetes mellitus risk in Finland: Selective genotyping of markers in the HLA-DQB1, HLA-DQA1 and HLA-DRB1 loci. Diabetic Medicine 1999, 16(12):985-992.
121. Norris J.M., Barriga K., Klingensmith G., Hoffman M., Eisenbarth G.S., Erlich H.A., et al. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA 2003, 290(13):1713-1720.
122. Norris J.M., Yin X., Lamb M.M., Barriga K., Seifert J., Hoffman M., et al. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA 2007, 298(12):1420-1428.
123. Owens M.J., Nemeroff C.B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacological Reviews 1991, 43(4):425-473.
124. Palmer J.P. Insulin autoantibodies: Their role in the pathogenesis of IDDM. Diabetes/Metabolism Reviews 1987, 3(4):1005-1015.
125. Pan X.R., Li G.W., Hu Y.H., Wang J.X., Yang W.Y., An Z.X., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997, 20(4):537-544.
126. Paronen J., Bjorksten B., Hattevig G., Akerblom H.K., Vaarala O. Effect of maternal diet during lactation on development of bovine insulin-binding antibodies in children at risk for allergy. The Journal of Allergy and Clinical Immunology 2000, 106(2):302-306.
127. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine 2008, 358(24):2560-2572.
128. Pearson E.R. Pharmacogenetics in diabetes. Current Diabetes Reports 2009, 9(2):172-181.
129. Perrin M., Donaldson C., Chen R., Blount A., Berggren T., Bilezikjian L., et al. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proceedings of the National Academy of Sciences of the United States of America 1995, 92(7):2969-2973.
130. Pistrosch F., Herbrig K., Kindel B., Passauer J., Fischer S., Gross P. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005, 54(7):2206-2211.
131. Pitt B. The anti-ischemic potential of angiotensin-converting enzyme inhibition: Insights from the heart outcomes prevention evaluation trial. Clinical Cardiology 2000, 23(7 Suppl. 4):IV9-IV14.
132. Rasmussen S.S., Glumer C., Sandbaek A., Lauritzen T., Borch-Johnsen K. Determinants of progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screened population: 3 year follow-up in the ADDITION study, Denmark. Diabetologia 2008, 51(2):249-257.
133. Reichard P., Nilsson B.Y., Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. The New England Journal of Medicine 1993, 329(5):304-309.
134. Reichel A., Schwarz J., Schulze J., Licinio J., Wong M.L., Bornstein S.R. Depression and anxiety symptoms in diabetic patients on continuous subcutaneous insulin infusion (CSII). Molecular Psychiatry 2005, 10(11):975-976.
135. Ricketts M.L., Verhaeg J.M., Bujalska I., Howie A.J., Rainey W.E., Stewart P.M. Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. The Journal of Clinical Endocrinology and Metabolism 1998, 83(4):1325-1335.
136. Rulifson I.C., Karnik S.K., Heiser P.W., ten Berge D., Chen H., Gu X., et al. Wnt signaling regulates pancreatic beta cell proliferation. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(15):6247-6252.
137. Ryan E.A., Paty B.W., Senior P.A., Bigam D., Alfadhli E., Kneteman N.M., et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005, 54(7):2060-2069.
138. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. The New England Journal of Medicine 1996, 335(14):1001-1009.
139. Salminen K., Sadeharju K., Lonnrot M., Vahasalo P., Kupila A., Korhonen S., et al. Enterovirus infections are associated with the induction of beta-cell autoimmunity in a prospective birth cohort study. Journal of Medical Virology 2003, 69(1):91-98.
140. Sandbaek A., Griffin S.J., Rutten G., Davies M., Stolk R., Khunti K., et al. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia 2008, 51(7):1127-1134.
141. Satterfield D.W., Volansky M., Caspersen C.J., Engelgau M.M., Bowman B.A., Gregg E.W., et al. Community-based lifestyle interventions to prevent type 2 diabetes. Diabetes Care 2003, 26(9):2643-2652.
142. Scheen A.J. ADOPT study: Which first-line glucose-lowering oral medication in type 2 diabetes?. Revue Médicale de Li[U+0450]ge 2007, 62(1):48-52.
143. Scherbaum W.A., Schweizer A., Mari A., Nilsson P.M., Lalanne G., Wang Y., et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes, Obesity & Metabolism 2008, 10(11):1114-1124.
144. Schmid J., Ludwig B., Schally A.V., Steffen A., Ziegler C.G., Block N.L., et al. Modulation of pancreatic islets-stress axis by hypothalamic releasing hormones and 11beta-hydroxysteroid dehydrogenase. Proceedings of the National Academy of Sciences of the United States of America 2010, 108(33):13722-13727.
145. Schrader J., Rennekamp W., Niebergall U., Schoppet M., Jahr H., Brendel M.D., et al. Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death. Diabetologia 2007, 50(6):1243-1247.
146. Schulze M.B., Hoffmann K., Boeing H., Linseisen J., Rohrmann S., Mohlig M., et al. An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care 2007, 30(3):510-515.
147. Schwarz P.E., Govindarajalu S., Towers W., Schwanebeck U., Fischer S., Vasseur F., et al. Haplotypes in the promoter region of the ADIPOQ gene are associated with increased diabetes risk in a German Caucasian population. Hormone and Metabolic Research 2006, 38(7):447-451.
148. Schwarz P.E., Li J., Wegner H., Bornstein S.R., Lindstrom J., Tuomilehto J. An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes: Response to Schulze et al. Diabetes Care 2007, 30(8):e87. author reply e88.
149. Schwarz P.E., Lindstrom J., Kissimova-Scarbeck K., Szybinski Z., Barengo N.C., Peltonen M., et al. The European perspective of type 2 diabetes prevention: Diabetes in Europe-Prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project. Experimental and Clinical Endocrinology and Diabetes 2008, 116(3):167-172.
150. Schwarz P.E., Odenbach C., Rothe U., Bergmann A., Bornstein S.R., Kunath H., et al. Prevention in occupational health care-A societal challenge. Medizinische Klinik (Munich, Germany) 2008, 103(4):210-216.
151. Schwarz P.E., Reimann M., Li J., Bergmann A., Licinio J., Wong M.L., et al. The Metabolic Syndrome-A global challenge for prevention. Hormone and Metabolic Research 2007, 39(11):777-780.
152. Seaberg R.M., Smukler S.R., Kieffer T.J., Enikolopov G., Asghar Z., Wheeler M.B., et al. Clonal identification of multipotent precursors from adult mouse pancreas that generate neural and pancreatic lineages. Nature Biotechnology 2004, 22(9):1115-1124.
153. Serr F., Lauer H., Armann B., Ludwig S., Thiery J., Fiedler M., et al. Sirolimus improves early microcirculation, but impairs regeneration after pancreatic ischemia-reperfusion injury. American Journal of Transplantation 2007, 7(1):48-56.
154. Shapiro A.M., Lakey J.R., Ryan E.A., Korbutt G.S., Toth E., Warnock G.L., et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. The New England Journal of Medicine 2000, 343(4):230-238.
155. Sharma A.M. The obese patient with diabetes mellitus: From research targets to treatment options. The American Journal of Medicine 2006, 119(5 Suppl. 1):S17-S23.
156. Sherry N.A., Chen W., Kushner J.A., Glandt M., Tang Q., Tsai S., et al. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 2007, 148(11):5136-5144.
157. Shu L., Sauter N.S., Schulthess F.T., Matveyenko A.V., Oberholzer J., Maedler K. Transcription factor 7-like 2 regulates beta-cell survival and function in human pancreatic islets. Diabetes 2008, 57(3):645-653.
158. Singh V.K., Fudenberg H.H. Binding of [125I]corticotropin releasing factor to blood immunocytes and its reduction in Alzheimer's disease. Immunology Letters 1988, 18(1):5-8.
159. Stene L.C., Joner G. Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: A large, population-based, case-control study. The American Journal of Clinical Nutrition 2003, 78(6):1128-1134.
160. Stene L.C., Ulriksen J., Magnus P., Joner G. Use of cod liver oil during pregnancy associated with lower risk of Type I diabetes in the offspring. Diabetologia 2000, 43(9):1093-1098.
161. Stewart P.M., Krozowski Z.S. 11 beta-Hydroxysteroid dehydrogenase. Vitamins and Hormones 1999, 57:249-324.
162. 2+ channel of rat pancreatic beta-cell in a cAMP-dependent manner. Diabetes 1997, 46(11):1755-1760.
163. Ta M., Choi Y., Atouf F., Park C.H., Lumelsky N. The defined combination of growth factors controls generation of long-term-replicating islet progenitor-like cells from cultures of adult mouse pancreas. Stem Cells 2006, 24(7):1738-1749.
164. Tang Q., Henriksen K.J., Bi M., Finger E.B., Szot G., Ye J., et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. The Journal of Experimental Medicine 2004, 199(11):1455-1465.
165. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The New England Journal of Medicine 1998, 339(19):1349-1357.
166. Thivolet C. New therapeutic approaches to type 1 diabetes: From prevention to cellular or gene therapies. Clinical Endocrinology 2001, 55(5):565-574.
167. Todd J.A. Genetic analysis of type 1 diabetes using whole genome approaches. Proceedings of the National Academy of Sciences of the United States of America 1995, 92(19):8560-8565.
168. Toyoda K., Okitsu T., Yamane S., Uonaga T., Liu X., Harada N., et al. GLP-1 receptor signaling protects pancreatic beta cells in intraportal islet transplant by inhibiting apoptosis. Biochemical and Biophysical Research Communications 2008, 367(4):793-798.
169. TRIGR Study Group Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR). Pediatric Diabetes 2007, 8(3):117-137.
170. Tselmin S., Korenblum W., Reimann M., Bornstein S.R., Schwarz P.E. The health status of Russian-speaking immigrants in Germany. Hormone and Metabolic Research 2007, 39(12):858-861.
171. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. The New England Journal of Medicine 2001, 344(18):1343-1350.
172. Ueda H., Howson J.M., Esposito L., Heward J., Snook H., Chamberlain G., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423(6939):506-511.
173. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317(7160):703-713.
174. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352(9131):854-865.
175. Ulgen F., Scherbaum W.A., Partke H.J., Bornstein S.R., Schinner S. Intrapancreatic adipocyte deposition in a mouse model of the metabolic syndrome. Hormone and Metabolic Research 2008, 40(7):507-509.
176. Vale W., Spiess J., Rivier C., Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981, 213(4514):1394-1397.
177. Vantyghem M.C., Marcelli-Tourvielle S., Pattou F., Noel C. Effects of non-steroid immunosuppressive drugs on insulin secretion in transplantation. Annales d'endocrinologie 2007, 68(1):21-27.
178. Vasavada R.C., Wang L., Fujinaka Y., Takane K.K., Rosa T.C., Mellado-Gil J.M., et al. Protein kinase C-zeta activation markedly enhances beta-cell proliferation: An essential role in growth factor mediated beta-cell mitogenesis. Diabetes 2007, 56(11):2732-2743.
179. Verge C.F., Gianani R., Kawasaki E., Yu L., Pietropaolo M., Jackson R.A., et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996, 45(7):926-933.
180. Voltarelli J.C., Couri C.E., Stracieri A.B., Oliveira M.C., Moraes D.A., Pieroni F., et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007, 297(14):1568-1576.
181. von Boehmer H. Type 1 diabetes: Focus on prevention. Nature Medicine 2004, 10(8):783-784.
182. Wente W., Efanov A.M., Brenner M., Kharitonenkov A., Koster A., Sandusky G.E., et al. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006, 55(9):2470-2478.
183. Wenzlau J.M., Juhl K., Yu L., Moua O., Sarkar S.A., Gottlieb P., et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(43):17040-17045.
184. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27(5):1047-1053.
185. Winkler C., Mollenhauer U., Hummel S., Bonifacio E., Ziegler A.G. Exposure to environmental factors in drinking water: Risk of islet autoimmunity and type 1 diabetes-The BABYDIAB study. Hormone and Metabolic Research 2008, 40(8):566-571.
186. Yach D., Stuckler D., Brownell K.D. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nature Medicine 2006, 12(1):62-66.
187. Zalutskaya A., Bornstein S.R., Mokhort T., Garmaev D. Did the Chernobyl incident cause an increase in Type 1 diabetes mellitus incidence in children and adolescents?. Diabetologia 2004, 47(1):147-148.
188. Zeggini E., Scott L.J., Saxena R., Voight B.F., Marchini J.L., Hu T., et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nature Genetics 2008, 40(5):638-645.
189. Zeggini E., Weedon M.N., Lindgren C.M., Frayling T.M., Elliott K.S., Lango H., et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007, 316(5829):1336-1341.
190. Zhang W., Patil S., Chauhan B., Guo S., Powell D.R., Le J., et al. FoxO1 regulates multiple metabolic pathways in the liver: Effects on gluconeogenic, glycolytic, and lipogenic gene expression. The Journal of Biological Chemistry 2006, 281(15):10105-10117.
191. Ziegler A.G., Hummel M., Schenker M., Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: The 2-year analysis of the German BABYDIAB Study. Diabetes 1999, 48(3):460-468.